Activated, functional ER can stimulate tumor growth and cell proliferation; therefore, it has been postulated that in most ER+ breast tumors, ER is the driving force underlying tumorigenesis, rendering it a principal target for treatment [5,6]. The gene discussed is ESR1; the disease is breast neoplasm.